New combo therapy for MDS shows promise in early trial
NCT ID NCT04878432
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tested a new drug called sabatolimab added to standard chemotherapy for people with intermediate to very high risk myelodysplastic syndrome (MDS), a type of blood cancer. The main goal was to check safety and side effects. A total of 39 adults took part, but the study was stopped early. The approach aims to control the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health Orlando
Orlando, Florida, 32803, United States
-
Arizona Oncology Associates
Tucson, Arizona, 85745, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mount Sinai Medical Center
New York, New York, 10029-6574, United States
-
SCRI-Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Texas Oncology San Antonio USO
San Antonio, Texas, 78240, United States
-
Tisch Hospital NYU Langone
New York, New York, 10016, United States
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
Uni of Massachusetts Medical Center
Worcester, Massachusetts, 01655, United States
-
University Hospitals Of Cleveland
Cleveland, Ohio, 44106, United States
-
University Of Michigan
Ann Arbor, Michigan, 48109, United States
-
Yale University School Of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.